Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Salim S. Virani, Julia M. Akeroyd, Vijay Nambi, Erin D. Michos, Pamela B. Morris, Khurram Nasir, Sidney C. Smith, Neil J. Stone, Laura A. Petersen, Christie M. Ballantyne

Research output: Contribution to journalLetterpeer-review

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)410-412
Number of pages3
Issue number3
StatePublished - Jan 15 2019


  • cholesterol
  • clinical trial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this